Hepatitis B virus infection in hemodialysis populations: progress toward prevention.
Hemodialysis patients are at increased risk of acquiring hepatitis B virus (HBV) infection. Administration of the standard HBV vaccine is suboptimal as a means of prevention because of an impaired seroconversion response in individuals with chronic kidney disease. Surquin and colleagues describe a novel vaccine adjuvant system that increases speed of seroconversion and duration of seroprotection compared with older vaccine formulations. However, its ability to improve overall seroconversion response remains unproven.
Barraclough
Katherine A
KA
Department of Nephrology, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia. katherine_barraclough@health.qld.gov.au
Playford
E Geoffrey
EG
D006509:Hepatitis B / Q000209:etiology / Q000517:prevention & control* / Q000628:therapy; D017325:Hepatitis B Vaccines / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D006435:Renal Dialysis / Q000009:adverse effects
D017325:Hepatitis B Vaccines